$30MSeries A, 19 May 2026
Launched with an FDA-cleared IND for ORJ-001 and plans a Phase 2 trial in IPF.
- Amount
- $30M
- Stage
- Series A
- Announced
- 19 May 2026
- Lead
- Westlake BioPartners
- Use of funds
- Launched with an FDA-cleared IND for ORJ-001 and plans a Phase 2 trial in IPF.
- Checked
- Announced by the company
- Sources
- Oorja Bio launches with $30M Series A biospace.com
Oorja Bio launches with $30M Series A pulse2.com